Big Pharma views compulsory licensing as only a last resort in India
This article was originally published in Scrip
Executive Summary
Leading research-based international pharmaceutical firms in the US and Europe have called for a measured approach to compulsory licensing in India, suggesting that the controversial tool be used only as "last resort" and in "exceptional circumstances".